WuXi Healthcare Ventures has led a first funding round for LifeMine Therapeutics, based on research by Harvard University profressor Gregory Verdine.

US-based biotechnology company LifeMine Therapeutics closed a $55m series A round yesterday led by WuXi Healthcare Ventures, the corporate venturing vehicle for medical research firm WuXi PharmaTech.

GV, Merck Ventures and Alexandria Venture Investments, respective subsidiaries of internet technology conglomerate Alphabet, pharmaceutical firm Merck & Co and life sciences real estate investment trut Alexandria Real Estate Equities, also participated.

The round was filled out by venture capital firms Foresite Capital and Arch Ventures, private equity firm Boyu Capital and investment…